Endocytosis and receptor degradation induced by anti-EGFR MAbs culminate in the inactivation of growth factor receptors and suppression of downstream signaling pathways, reducing the proliferative/survival potential of cancer cells [3,17,18]. This evidence concerns the gene EGFR and cancer.